1-5 of 5
Giorgio Scagliotti
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Abstract 1536: Deciphering the crosstalk within the tumor microenvironment of NSCLC by a virtual microdissection approach

Sushant Parab, Francesca Napoli, Davide Corà, Gabriella Doronzo, Valentina Communanza, Luisella Righi, Luca Primo, Valentina Monica, Lorenzo Manganaro, Bianco Selene, Paolo Bironzo, Giorgio Scagliotti, Federico Bussolino
Journal: Cancer Research
Cancer Res (2024) 84 (6_Supplement): 1536.
https://doi.org/10.1158/1538-7445.AM2024-1536
Published: 22 March 2024
View articletitled, Abstract 1536: Deciphering the crosstalk within the tumor microenvironment of NSCLC by a virtual microdissection approach
Journal Articles

Abstract CT027: TALAPRO-1 final data: Talazoparib (TALA) monotherapy in men with DNA damage response alterations (DDRalt) and metastatic castration-resistant prostate cancer (mCRPC): Exploration of DDRalt germline/somatic origin and zygosity

Johann S. de Bono, A. Douglas Laird, Niven Mehra, Philippe Barthelemy, Remy Delva, Tanya Dorff, Umberto Basso, Adam Stirling, Jean-Pascal Machiels, Herlinde Dumez, Vincent Renard, Julia Hopkins, Lee A. Albacker, Hsiang-Chun Chen, Marielena Mata, Nicola Di Santo, Cynthia Healy, Inge M. van Oort, Giorgio Scagliotti, Karim Fizazi
Journal: Cancer Research
Cancer Res (2021) 81 (13_Supplement): CT027.
https://doi.org/10.1158/1538-7445.AM2021-CT027
Published: 01 July 2021
View articletitled, Abstract CT027: TALAPRO-1 final data: Talazoparib (TALA) monotherapy in men with DNA damage response alterations (DDRalt) and metastatic castration-resistant prostate cancer (mCRPC): Exploration of DDRalt germline/somatic origin and zygosity
Journal Articles

Abstract 560: Retrospective evaluation, of the randomized Phase 3 MARQUEE trial of tivantinib (T) + erlotinib (E) versus placebo (P) + erlotinib (E) using VeriStrat in patients with previously treated nonsquamous NSCLC

Giorgio Scagliotti, Wallace Akerley, Joachim von Pawel, Joanna Roder, Dale Shuster, Brian Schwartz, Dominic Spinella
Journal: Cancer Research
Cancer Res (2015) 75 (15_Supplement): 560.
https://doi.org/10.1158/1538-7445.AM2015-560
Published: 01 August 2015
View articletitled, Abstract 560: Retrospective evaluation, of the randomized Phase 3 MARQUEE trial of tivantinib (T) + erlotinib (E) versus placebo (P) + erlotinib (E) using VeriStrat in patients with previously treated nonsquamous NSCLC
Journal Articles

Abstract 4682: Sunitinib (SU) in advanced NSCLC: Correlation of circulating biomarkers with clinical outcome

Charles S. Harmon, Sam E. DePrimo, Mark Socinski, Giorgio Scagliotti, Rafael Rosell, Ramaswamy Govindan, Ray D. Page, John Hainsworth, Julie R. Brahmer, Normand Blais, Silvia Novello, Lesley Tye, Sindy Kim, James A. Williams, Richard Chao
Journal: Cancer Research
Cancer Res (2010) 70 (8_Supplement): 4682.
https://doi.org/10.1158/1538-7445.AM10-4682
Published: 15 April 2010
View articletitled, Abstract 4682: Sunitinib (SU) in advanced NSCLC: Correlation of circulating biomarkers with clinical outcome
Journal Articles

Correlation of Serum Metalloproteinase Levels with Lung Cancer Metastasis and Response to Therapy

Spiridione Garbisa, Giorgio Scagliotti, Laura Masiero, Carla Di Francesco, Cristina Caenazzo, Maurizio Onisto, Marco Micela, William G. Stetler-Stevenson, Lance A. Liotta
Journal: Cancer Research
Cancer Res (1992) 52 (16): 4548–4549.
Published: 01 August 1992
View articletitled, Correlation of Serum Metalloproteinase Levels with Lung Cancer Metastasis and Response to Therapy
Open the PDF for Correlation of Serum Metalloproteinase Levels with Lung Cancer Metastasis and Response to Therapy in another window